BIO-PATH HOLDINGS, INC. Files S-1 Registration Statement

TL;DR

<b>BIO-PATH HOLDINGS, INC. has filed an S-1 registration statement with the SEC for securities offerings.</b>

AI Summary

BIO-PATH HOLDINGS, INC. (BPTH) filed a IPO Registration (S-1) with the SEC on April 24, 2024. BIO-PATH HOLDINGS, INC. filed an S-1 registration statement with the SEC on April 24, 2024. The filing is for registration under the Securities Act of 1933. The company's principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401. The IRS Employer Identification Number is 87-0652870. The Standard Industrial Classification Code Number is 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking BIO-PATH HOLDINGS, INC., this filing contains several important signals. This S-1 filing indicates the company is preparing for a public offering of securities, which could provide capital for operations, research, or expansion. The filing provides detailed information about the company's business, financial condition, and management, allowing potential investors to assess risks and opportunities.

Risk Assessment

Risk Level: low — BIO-PATH HOLDINGS, INC. shows low risk based on this filing. The filing is a standard S-1 registration statement, which is a preliminary step for public offerings and does not contain specific financial performance data or operational updates that would indicate immediate risk.

Analyst Insight

Monitor future filings for details on the proposed securities offering, including the number of shares, pricing, and use of proceeds.

Key Numbers

• 2024-04-24 — Filing Date (Date the S-1 registration statement was filed)
• 2834 — SIC Code (Pharmaceutical Preparations)
• 87-0652870 — IRS EIN (Employer Identification Number)
• 333-278910 — SEC File Number (Registration Number)

Key Players & Entities

• BIO-PATH HOLDINGS, INC. (company) — Registrant
• Peter H. Nielsen (person) — President and Chief Executive Officer
• William R. Rohrlich, II (person) — Copies To
• Winstead PC (company) — Legal Counsel
• 2834 (dollar_amount) — Primary Standard Industrial Classification Code Number
• 87-0652870 (dollar_amount) — I.R.S. Employer Identification Number
• 333-278910 (dollar_amount) — SEC File Number

FAQ

Industry Context

The company operates in the Pharmaceutical Preparations industry (SIC Code 2834).

Regulatory Implications

The S-1 filing is made under the Securities Act of 1933, which governs the registration of new securities offerings.

What Investors Should Do

1. Review the full S-1 filing for detailed business descriptions and risk factors.
2. Track subsequent SEC filings for updates on the proposed securities offering.
3. Research the company's market and competitive landscape within the pharmaceutical preparations sector.

Key Dates

• 2024-04-24: S-1 Filing — Registration statement filed with the SEC.

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing to compare against for 'vs last filing' data.

Key Financial Figures

• $0.001 — 0 shares of our common stock, par value $0.001 per share, which consists of (i) 75,000
• $3.865 — onal shares), with an exercise price of $3.865 per share, issued in a private placemen
• $4.9875 — onal shares), with an exercise price of $4.9875 per share, issued on March 27, 2024 to
• $3.10 — onal shares), with an exercise price of $3.10 per share, issued in a private placemen
• $4.0313 — onal shares), with an exercise price of $4.0313 per share, issued on April 19, 2024 to
• $2.92 — aq Capital Market on April 22, 2024 was $2.92 per share. Investing in our securitie

Filing Documents

• tm2412459-1_s1.htm (S-1) — 388KB
• tm2412459d2_ex5-1.htm (EX-5.1) — 11KB
• tm2412459d2_ex23-1.htm (EX-23.1) — 3KB
• tm2412459d2_ex-filingfees.htm (EX-FILING FEES) — 28KB
• lg_biopathholdings-4clr.jpg (GRAPHIC) — 16KB
• tm2412459d2_ex5-1img001.jpg (GRAPHIC) — 8KB
• 0001104659-24-051250.txt (&nbsp;) — 464KB

RISK FACTORS

RISK FACTORS 8 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 9

USE OF PROCEEDS

USE OF PROCEEDS 11 SELLING STOCKHOLDERS 12 PLAN OF DISTRIBUTION 15

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 17 LEGAL MATTERS 19 EXPERTS 19 WHERE YOU CAN FIND MORE INFORMATION 19 INFORMATION INCORPORATED BY REFERENCE 19 i TABLE OF CONTENTS ABOUT THIS PROSPECTUS This prospectus relates to the resale from time to time of up to 483,750 shares of our common stock, par value $0.001 per share, which consists of (i) 75,000 shares of common stock issuable upon the exercise of warrants (including shares that may be issued to the holder in lieu of fractional shares), with an exercise price of $3.865 per share, issued in a private placement on March 27, 2024, (ii) 5,625 shares of common stock issuable upon the exercise of placement agent warrants (including shares that may be issued to the holder in lieu of fractional shares), with an exercise price of $4.9875 per share, issued on March 27, 2024 to H.C. Wainwright & Co., LLC as compensation in connection with the private placement and registered direct offering that closed on March 27, 2024, (iii) 375,000 shares of common stock issuable upon the exercise of warrants (including shares that may be issued to the holder in lieu of fractional shares), with an exercise price of $3.10 per share, issued in a private placement on April 19, 2024 and (iv) 28,125 shares of common stock issuable upon the exercise of placement agent warrants (including shares that may be issued to the holder in lieu of fractional shares), with an exercise price of $4.0313 per share, issued on April 19, 2024 to H.C. Wainwright & Co., LLC as compensation in connection with the private placement and registered direct offering that closed on April 19, 2024. Before buying any of the common stock that the selling stockholders are offering, we urge you to carefully read this prospectus, together with the information incorporated by reference as described under the headings "Where You Can Find More Information" and "Information Incorporated By Reference" in this prospectus. These documents contain important informatio

View Full Filing

View this S-1 filing on SEC EDGAR